key: cord-0919169-2x5cfmc2
authors: Nguyen, Nhu Ngoc; Houhamdi, Linda; Hoang, Van Thuan; Stoupan, Didier; Fournier, Pierre-Edouard; Raoult, Didier; Colson, Philippe; Gautret, Philippe
title: High rate of reinfection with the SARS-CoV-2 Omicron variant
date: 2022-04-23
journal: J Infect
DOI: 10.1016/j.jinf.2022.04.034
sha: 787682f8d6d51efe5aa6578bf13151cec480751d
doc_id: 919169
cord_uid: 2x5cfmc2

nan

• In Marseille, there were five major epidemics of COVID-19 due to different variants • Reinfection rates with SARS-CoV-2 were 0.2, 0.3 and 1.5% in previous epidemics • During the ongoing Omicron variant epidemic, the reinfection rate increased to 6.8%

• The protection against Omicron due to a previous infection is markedly reduced Dear Editor,

We read with interest that infection with Omicron variant can occur in patients who presented a high antibody titer, even though their concentration was at 2.4 higher than infection with Delta variant [1] . The SARS-CoV-2 pandemic has shown the succession or superposition of epidemics linked to numerous viral variants [2] . Until recently, the overall rate of reinfection 2 with SARS-CoV-2 has been relatively low, below 2% according to several international studies [3] , [4] . The Omicron (B.1.1.529) variant has been described for the first time on November 2021 in Gauteng province, South Africa and spread rapidly worldwide. One study conducted in South Africa demonstrated that it was associated with an increased hazard ratio of reinfection, suggesting its substantial ability to evade immunity from prior infection [5] . In addition, vaccine efficacy against this variant was reported to be reduced to around 56% for the Pfizer vaccine [6] .

We report here the incidence and proportion of reinfections with the Omicron variant among patients diagnosed in our institute.

Our laboratory has massively screened SARS-CoV-2 infections by real-time reverse transcription-PCR (qPCR) under the same conditions since the emergence of this virus in France in February 2020. We thus have a cohort of patients screened and diagnosed as infected for the period February 27, 2020-March 6, 2022, making it possible to calculate the rate of reinfections over this entire period without the bias of variable screening strategy or capacity. An automatic reinfection detection system has been implemented through the laboratory information system of our institute's laboratory, on the basis of two qPCR-positive samples spaced at least 90 days apart with a negative qPCR between two episodes, according to the CDC definition of reinfection case [https://www.cdc.gov/coronavirus/2019ncov/php/invest-criteria.html]. SARS-CoV-2 RNA genotyping was performed by using sequencing or variant-specific qPCR, as described elsewhere [3] . previous assessment that this estimated risk decreased over time [3] , we observed little variation, between 2.4 and 3.0%, in this updated study. This is likely because of cumulative numbers of reinfections overtime with occurrence of new cases of reinfection that were diagnosed after our previous assessment.

The increase in the proportion of reinfections with the Omicron variant is additional evidence that the genetic variability of SARS-CoV-2 has resulted in antigenic changes leading to reduced protection conferred by a previous infection. Our recent observations of a lower severity of infections with the Omicron variants as indicated by low rates of hospitalization, transfer to intensive care units, and death is good news in this context [9], [10] . The Omicron variant is likely distantly related to other SARS-CoV-2 variants which may account for a higher rate on reinfection and lower efficacy of vaccines. Indeed, despite the currently considerable proportions of people vaccinated and/or infected in France, present data and recently published data [5] suggest that resulting immunity could not prevent an endemicization of SARS-CoV-2.

The authors have no conflicts of interest to declare relative to the present study. Didier Raoult was a consultant for the Hitachi High-Technologies Corporation, Tokyo, Japan from 2018 to 2020. He is a scientific board member of the Eurofins company and a founder of a microbial culture company (Culture Top). Funding sources had no role in the design and con-duct of the 5 study, the collection, management, analysis, and interpretation of the data, and the preparation, review, or approval of the manuscript. 

Antibody titers and breakthrough infections with Omicron SARS-CoV-2

Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review

SARS-CoV-2 reinfection and COVID severity

Reinfection Rates Among Patients Who Previously Tested Positive for Coronavirus Disease 2019: A Retrospective Cohort Study

Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa

Effectiveness of COVID-19 vaccines against Omicron or Delta infection

Analysis of SARS-CoV-2 variants from 24,181 patients exemplifies the role of globalization and zoonosis in pandemics

Does SARS-CoV-2 re-infection depend on virus variant ?

Omicron variant cases

Severity of the first 207 infections with the SARS-CoV-2 Omicron BA.2 variant